Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New $1.41 Million Investment in Ultragenyx Pharmaceutical Inc. $RARE

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 4th quarter, Holdings Channel.com reports. The fund purchased 61,329 shares of the biopharmaceutical company’s stock, valued at approximately $1,411,000.

Several other large investors have also recently made changes to their positions in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after acquiring an additional 29,984 shares in the last quarter. Creative Planning purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $454,000. American Century Companies Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $366,000. M&T Bank Corp increased its stake in shares of Ultragenyx Pharmaceutical by 19.7% in the second quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 1,192 shares during the period. Finally, Amundi increased its stake in shares of Ultragenyx Pharmaceutical by 1,560.4% in the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after buying an additional 93,189 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Up 1.5%

Shares of RARE stock opened at $23.71 on Friday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37. The stock has a market cap of $2.34 billion, a PE ratio of -3.88 and a beta of 0.39. The company’s fifty day moving average price is $23.20 and its 200-day moving average price is $26.14.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter last year, the firm posted ($1.57) EPS. The business’s quarterly revenue was down 2.2% on a year-over-year basis. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on RARE. HC Wainwright decreased their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Wall Street Zen downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Canaccord Genuity Group reduced their price objective on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Finally, Cantor Fitzgerald boosted their price objective on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $59.88.

Insider Buying and Selling

In related news, insider John Richard Pinion sold 10,029 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $228,661.20. Following the transaction, the insider owned 110,026 shares in the company, valued at $2,508,592.80. The trade was a 8.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Howard Horn sold 8,409 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the transaction, the chief financial officer owned 86,669 shares in the company, valued at approximately $1,967,386.30. The trade was a 8.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 117,262 shares of company stock worth $2,687,403 over the last quarter. 5.20% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.